Adaptimmune Therapeutics plc American (ADAP) EPS by Year
ADAP
Adaptimmune Therapeutics plc American lost $0.05 per diluted share in fiscal year 2024. This represents an increase of 44.4% from the prior fiscal year. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters Adaptimmune Therapeutics plc American has filed alongside them.
FY2024 annual
EPS (Diluted)-$0.05
YoY+44.4%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2025, ended Jun 30, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
ADAP EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Metric
FY24
FY23
FY22
FY21
FY20
FY19
FY18
FY17
FY16
FY15
FY14
FY13
EPS (Diluted)
-$0.05+44.4%
-$0.09+47.1%
-$0.170.0%
-$0.17-13.3%
-$0.15+31.8%
-$0.22
N/A
N/A
N/A
N/A
N/A
N/A
ADAP EPS (Diluted) by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
More Adaptimmune Therapeutics plc American financials
What was Adaptimmune Therapeutics plc American's diluted earnings per share in fiscal year 2024?
Adaptimmune Therapeutics plc American lost $0.05 per diluted share in fiscal year 2024.
How fast is Adaptimmune Therapeutics plc American's diluted earnings per share growing?
Adaptimmune Therapeutics plc American (ADAP) diluted earnings per share rose by 44.4% year over year, from -$0.09 to -$0.05 in fiscal year 2024.
What was Adaptimmune Therapeutics plc American's diluted earnings per share in the most recent quarter?
Adaptimmune Therapeutics plc American (ADAP) reported -$0.02 in diluted earnings per share in Q2 2025. This represents a decrease of 150.0% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Adaptimmune Therapeutics plc American (ADAP) reported on that line in every period on record.
